Want to see MRK full AI Analyst Report?

Merck & Company (MRK) Stock Forecast & Price Target

15,048 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRK Analyst Ratings

Strong Buy

13 Buy

4 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

$153.63

▼(-1.81% Downside)

Based on 17 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $153.63 with a high forecast of $180.00 and a low forecast of $105.00. The average price target represents a -1.81% change from the last price of $156.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"$75","128":"$128","181":"$181","101.5":"$101.5","154.5":"$154.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":153.625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$153.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,101.5,128,154.5,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.2,134.0307692307692,137.86153846153846,141.69230769230768,145.52307692307693,149.35384615384615,153.18461538461537,157.01538461538462,160.84615384615384,164.67692307692306,168.5076923076923,172.33846153846153,176.16923076923078,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.2,132.00192307692308,133.80384615384614,135.60576923076923,137.4076923076923,139.20961538461538,141.01153846153846,142.81346153846152,144.6153846153846,146.4173076923077,148.21923076923076,150.02115384615385,151.8230769230769,{"y":153.625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.2,128.26153846153846,126.32307692307691,124.38461538461537,122.44615384615383,120.5076923076923,118.56923076923076,116.63076923076923,114.6923076923077,112.75384615384615,110.81538461538462,108.87692307692308,106.93846153846154,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.724,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.398,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.075,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.02,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.509,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.732,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.656,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.977,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.359,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.347,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.37,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$180.00

Average Price Target$153.63

Lowest Price Target$105.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Trung Huynh

RBC Capital

$150

Hold

-4.12%

Downside

Reiterated

08/25/26

RBC Capital Reaffirms Their Hold Rating on Merck & Company (MRK)

Louise Chen

Scotiabank

$155

Buy

-0.93%

Downside

Reiterated

08/25/26

Merck & Company (MRK) Gets a Buy from Scotiabank

Alexandria Hammond

Wolfe Research

$155→$180

Buy

15.05%

Upside

Reiterated

08/25/26

Merck price target raised to $180 from $155 at Wolfe ResearchMerck price target raised to $180 from $155 at Wolfe Research

Jasper Hellweg

Argus Research

$145→$170

Buy

8.66%

Upside

Reiterated

08/24/26

Merck price target raised to $170 from $145 at ArgusMerck price target raised to $170 from $145 at Argus

Evan Seigerman

BMO Capital

$142→$170

Buy

8.66%

Upside

Reiterated

08/20/26

BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)

Asad Haider

Goldman Sachs

$140→$160

Buy

2.27%

Upside

Assigned

08/20/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Moderna (NASDAQ: MRNA) and Akari Therapeutics (NASDAQ: AKTX)

Courtney Breen

Bernstein

$100→$105

Hold

-32.89%

Downside

Assigned

08/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Merck & Company (NYSE: MRK) and Sight Sciences (NASDAQ: SGHT)

Michael Yee

UBS

$145→$175

Buy

11.86%

Upside

Reiterated

08/20/26

Merck price target raised to $175 from $145 at UBSMerck price target raised to $175 from $145 at UBS

Jason Gerberry

Bank of America Securities

$141→$166

Buy

6.10%

Upside

Reiterated

08/19/26

Merck price target raised to $166 from $141 at BofAMerck price target raised to $166 from $141 at BofA

Mohit Bansal

Wells Fargo

$150

Buy

-4.12%

Downside

Assigned

08/19/26

Merck & Company (MRK) Receives a Buy from Wells Fargo

Terence Flynn

Morgan Stanley

$116→$179

Buy

14.41%

Upside

Upgraded

08/19/26

Merck upgraded to Overweight from Equal Weight at Morgan StanleyMerck upgraded to Overweight from Equal Weight at Morgan Stanley

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

08/19/26

Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Moderna (NASDAQ: MRNA) and Merck & Company (NYSE: MRK)

Emily Field

Barclays

$150

Buy

-4.12%

Downside

Reiterated

08/13/26

Merck & Company (MRK) Gets a Buy from Barclays

Luisa Hector

Berenberg Bank

$127

Hold

-18.82%

Downside

Reiterated

08/05/26

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

Vamil Divan

Guggenheim

$145→$146

Buy

-6.68%

Downside

Reiterated

08/04/26

Merck price target raised to $146 from $145 at GuggenheimMerck price target raised to $146 from $145 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Trung Huynh

RBC Capital

$150

Hold

-4.12%

Downside

Reiterated

08/25/26

RBC Capital Reaffirms Their Hold Rating on Merck & Company (MRK)

Louise Chen

Scotiabank

$155

Buy

-0.93%

Downside

Reiterated

08/25/26

Merck & Company (MRK) Gets a Buy from Scotiabank

Alexandria Hammond

Wolfe Research

$155→$180

Buy

15.05%

Upside

Reiterated

08/25/26

Merck price target raised to $180 from $155 at Wolfe ResearchMerck price target raised to $180 from $155 at Wolfe Research

Jasper Hellweg

Argus Research

$145→$170

Buy

8.66%

Upside

Reiterated

08/24/26

Merck price target raised to $170 from $145 at ArgusMerck price target raised to $170 from $145 at Argus

Evan Seigerman

BMO Capital

$142→$170

Buy

8.66%

Upside

Reiterated

08/20/26

BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)

Asad Haider

Goldman Sachs

$140→$160

Buy

2.27%

Upside

Assigned

08/20/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Moderna (NASDAQ: MRNA) and Akari Therapeutics (NASDAQ: AKTX)

Courtney Breen

Bernstein

$100→$105

Hold

-32.89%

Downside

Assigned

08/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Merck & Company (NYSE: MRK) and Sight Sciences (NASDAQ: SGHT)

Michael Yee

UBS

$145→$175

Buy

11.86%

Upside

Reiterated

08/20/26

Merck price target raised to $175 from $145 at UBSMerck price target raised to $175 from $145 at UBS

Jason Gerberry

Bank of America Securities

$141→$166

Buy

6.10%

Upside

Reiterated

08/19/26

Merck price target raised to $166 from $141 at BofAMerck price target raised to $166 from $141 at BofA

Mohit Bansal

Wells Fargo

$150

Buy

-4.12%

Downside

Assigned

08/19/26

Merck & Company (MRK) Receives a Buy from Wells Fargo

Terence Flynn

Morgan Stanley

$116→$179

Buy

14.41%

Upside

Upgraded

08/19/26

Merck upgraded to Overweight from Equal Weight at Morgan StanleyMerck upgraded to Overweight from Equal Weight at Morgan Stanley

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

08/19/26

Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Moderna (NASDAQ: MRNA) and Merck & Company (NYSE: MRK)

Emily Field

Barclays

$150

Buy

-4.12%

Downside

Reiterated

08/13/26

Merck & Company (MRK) Gets a Buy from Barclays

Luisa Hector

Berenberg Bank

$127

Hold

-18.82%

Downside

Reiterated

08/05/26

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

Vamil Divan

Guggenheim

$145→$146

Buy

-6.68%

Downside

Reiterated

08/04/26

Merck price target raised to $146 from $145 at GuggenheimMerck price target raised to $146 from $145 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months

Asad HaiderGoldman Sachs

Success Rate

12/13 ratings generated profit

Average Return

+13.04%

Copying Asad Haider's trades and holding each position for 3 Months would result in 92.31% of your transactions generating a profit, with an average return of +13.04% per trade.

1 Year

Asad HaiderGoldman Sachs

Success Rate

13/13 ratings generated profit

Average Return

+45.86%

Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +45.86% per trade.

2 Years

Asad HaiderGoldman Sachs

Success Rate

13/13 ratings generated profit

Average Return

+57.15%

Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +57.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRK has received 51 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. MRK average Analyst price target in the past 3 months is 153.63.

Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is $2.21 with a range of $2.01 to $2.41. The previous quarter’s EPS was -$0.13. MRK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is $17.31B with a range of $16.75B to $17.84B. The previous quarter’s sales results were $16.58B. MRK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 153.63.

What is MRK’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MRK, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRK a Buy, Sell or Hold?

Merck & Company has a consensus rating of Strong Buy which is based on 13 buy ratings, 4 hold ratings and 0 sell ratings.

What is Merck & Company’s price target?

The average price target for Merck & Company is 153.63. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $180.00 ,the lowest forecast is $105.00. The average price target represents -1.81% Decrease from the current price of $156.45.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of MRK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Merck & Company (MRK) Stock Forecast & Price Target

MRK Analyst Ratings

MRK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

MRK Analyst Recommendation Trends

MRK Financial Forecast

MRK Earnings Forecast

MRK Sales Forecast

MRK Stock Forecast FAQ

Detailed List of Analyst Forecasts